Microfluidics for Pharmaceutical Applications: From Nano/Micro Systems Fabrication to Controlled Drug Delivery

Antonio Francesko[1,#], Vanessa F. Cardoso[1,2,#], Senentxu Lanceros-Méndez[3,4]

[1]Centro de Física, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal

[2]CMEMS-UMinho, Universidade do Minho, DEI, Campus de Azurém, Guimarães 4800-058, Portugal

[3]BCMaterials, Parque Científico y Tecnológico de Bizkaia, 48160-Derio, Spain

[4]IKERBASQUE, Basque Foundation for Science, 4803, Bilbao, Spain

[#] equal contribution

Abstract

This chapter presents and overview of the main topics related to microfluidics for pharmaceutical applications. It begins with a general introduction on lab-on-a-chip technology and microfluidics, in which the main definitions, concepts and characteristics are presented. Further, the main materials and processing techniques used for the development of microfluidic systems are introduced. Finally, the most representative applications are discussed. Applications are focusing on the areas of drug development, drug delivery and diagnosis, cell-based devices and organs-on-a-chip devices, the latest step towards whole body models. Thus, a complete overview in the area is provided, followed by a summary and outlook on open questions and future trends.

Keywords: microfluidics; pharmaceutical applications; lab-on-a-chip; organ-on-a-chip; drug testing

"Everything in excess is opposed to nature"
Hippocrates (460 BC - 377 BC)

1. Introduction

Since the introduction of a miniaturized gas chromatography analyzer on a silicon wafer in the 1970s by Terry *et al.* (Terry et al., 1979) and most prominently since the conceptual work on a miniaturized total-chemical analysis systems by Manz *et al.* in 1990 (Manz et al., 1990), the field of micro total analysis systems (µTAS) or lab-on-a-chip technology (LOC) has been under intensive development in many biotechnological areas spanning from basic theoretical models and academic proof-of-concept studies to commercial applications. LOC are ideally described as miniature versions of their macroscale counterparts and therefore usually integrate all the component units of a complete laboratory essay (Rios et al., 2012). The term microfluidic is generally used to describe the precise control and manipulation of small volume of fluids on a micrometer scale, which is the basis of LOC systems. The attractiveness of such miniaturized systems can be attributed in large part to its size-effect, which allows portability, low consumption of sample/reagents and power and short essay time. Further, it is associated to some unique physical phenomena that emerge at such scale and bring numerous benefits in pharmaceutical applications from the early drug discovery and screening stage to the final targeted and controlled delivery stage, as will be addressed later (Maguire et al., 2009). The high interdisciplinarity of this technology has received inputs from a large spectra of researchers from different areas of expertise in order to develop and apply microfludics in a wide range of (bio)technological applications, such as clinical diagnostic (Chin et al., 2012), proteomic (Chao and Hansmeier, 2013), cell and tissue engineering (Inamdar and Borenstein, 2011), pharmacology (Skardal et al., 2016) and environmental monitoring (Li and Lin, 2009), among others (Chin et al., 2007, Sackmann et al., 2014). The value of this technology is demonstrated by the growing number and improved quality of published papers (Mark et al., 2010). According to the ISI Web of Science, about 45 000 of documents related to microfluidic have been published since 2000 being almost 10 % related to pharmaceutical applications (Figure 1).



Figure 1: Published items related to “microfluidic” by year since 2000. Data from ISI Web of Science.

This strong growth over the years along with the potential to produce revolutionary and practical miniaturized devices has led to the emergence of a number of companies dedicated to microfluidics and LOC for different application areas, being approximately 274 worldwide in February 2016 (FluidicMEMS, 2016). Some examples are Abaxis (diagnostics), Advanced Liquid Logic (research instruments), Biosite (diagnostics), Chiral Photonics (packaging, prototyping, manufacturing), Aixtek (consulting), FlowJEM (prototyping), Microfluidic Imaging (imaging), Cepheid (diagnostics), Cytonome (therapeutics), Micronics (custom development, manufacturing, research instruments), Microflow Laboratory (consulting, prototyping), Medtronic (medical devices), Luna Innovations (contract R&D), Aline Inc. (development, components) and i-STAT (diagnostics). This technological boom led MIT Technology Review to nominate microfluidic as one of the ten technologies that will change the world, with particular relevance in the life science area (Weigl et al., 2003).

The present chapter provides a general description of the essential components and properties of LOC systems, including concepts of materials and fabrication techniques . Further, their applications in relevant biotechnological fields are presented and discussed. In particular, the applicability and advantages of microfluidic technologies in the pharmacological area will be highlighted. The main objective is to provide an overview to scientists and engineers on the possibilities and potential offered by microfluidic technologies to develop innovative and improved products for drugs discovery and development.

2. Definition, main concepts and characteristics

As briefly described above, LOC systems are based on a broader technology called microfluidics, the science and engineering of manipulating and processing small volumes of fluids (typically 100 nl to 10 µl of samples and reagents) in microchannels that have at least one dimension (e.g. channel width, depth or diameter) with length scale from ten to hundred of micrometers. LOC are often described as miniaturized versions of their macroscale counterparts. This means that successful operation of technically complex essays on-chip are designed to include all or most of the components and stages of a complete laboratory procedure in an integrated, automated and small platform (Figure 2) (Chin et al., 2012). Theses stages can include sampling, sample pre-treatment, chemical reactions, product separation and isolation, detection system and data analysis, among others (Bjornmalm et al., 2014). Therefore, different kinds of components such as filters, pumps, valves, actuators, heaters, motors and other functional units have been miniaturized. Likewise, detection systems such as sensors and detectors, including optical, magnetic and electrical detection, and all the associated electronics, have been developed, integrated and successfully applied in LOC (Dittrich and Manz, 2006).



Figure 2: General components of a LOC .

The strong decrease in the length scale gives rise to unique, important and sometimes non-intuitive phenomena at the microscale that are not present at the macroscopic scale and are essential for many biotechnological applications. In this context, fluid flow can be typically characterized by two regimes: laminar or turbulent, which is defined by the relative contribution of inertial and viscous forces on a fluid flowing in a channel. It is usually described by the Reynolds number (*Re*), a dimensionless parameters defined by the density and viscosity of the fluid, plus the average velocity of the fluid flow and the characteristic length scale (e.g. diameter of the channel) (Pihl et al., 2005, Weigl et al., 2003). The transition between laminar and turbulent flow typically occurs above a *Re* of 2000 in internal flows (Weigl et al., 2003). Inertial forces dominate at

larger *Re,* while viscous forces govern at low *Re*. Therefore, reducing the characteristic length scale has the same effect on the fluid behavior in terms of *Re* as increasing the viscosity of the solution. This means that in microfluidic systems, flows are well below *Re* of hundred or even below unity and so the flow is truly laminar, dominated by viscous forces. Thus, the fluid velocity is invariant with time at all locations when the boundary conditions are constant (Pihl et al., 2005). As a consequence, fluid streams flow parallel to each other and mixture between them occurs just through convective and molecular diffusion. This enables the design of separation and detection devices on laminar fluid diffusion interfaces (Yildiz, 2016, Pamme, 2007, Lenshof and Laurell, 2010). However, this fact has also important implications in many applications requiring the mixture of fluids, especially when low diffusive coefficients are presents. Nevertheless, to overcome this limitation, powerful passive and active mixers have been developed and successfully integrated in microfluidic systems (Naher et al., 2011, Capretto et al., 2011, Cardoso et al., 2014). Another critical issue to considerer in microfluidic system is the fluid transport system, i.e. sample introduction and/or extraction. In fact, flow rates ranging between hundred of microliter per minute for high-volume-throughput down to picoliter per minute for applications requiring micron to submicron sized channel must be obtained using precise fluid drivers (Luo et al., 2009, Byun et al., 2014). To achieve such requirements, two main methods have been employed. Microfluidic channels made of materials that are charged under experimental conditions are used to induce the well-known phenomenon of electroosmotic flow (EOF). In this case, a blunt fluid flow profile is obtained (Figure 3a), being however susceptible to variation of channel wall coating and fluid composition, limiting its use as generic pumping system (Brask et al., 2005, Gaudioso and Craighead, 2002). In turn, pressure-driven flow by using mechanical positive displacement pumping shows the advantage of very little compliance, which allows controlling the exact volume of pumped fluid and knowing the exact location of the fluid meniscus within the microchannel. A particularity of this system is that the fluid flow exhibits a non-uniform velocity profile, which is usually pseudo-parabolic, i.e. maximum at the center of the microchannel and decreasing to zero velocity immediately near to the channel walls (Figure 3b) (Brody et al., 1996, Chovan and Guttman, 2002). Such systems are mechanically complex, hard to miniaturize and very low flow rates are generally difficult to obtain. Nevertheless, these fluidic transport systems have demonstrated their suitability in many biotechnological applications, being the system of election by most of the researcher in this area (Weigl et al., 2003).



Figure 3: Schematic representation of (a) electroosmotic flow; (b) pressure-driven flow.

In view of the above and from a technological point-of-view, it is possible to claim that LOC technology offers many unique benefits when compared to larger-scale conventional systems that include: (i) miniaturized devices, allowing portability, *in-situ* measurements and development of point-of-care systems; (ii) minute consumption of fluids, ideal for handling costly and difficult-to-obtain samples and reagents; (iii) reduced production of waste, making then environmental friendly; (iv) reduced energy consumption; (v) ability to perform high-throughput analysis by processing several assays in parallel; (vi) quick reaction and fast analysis, allowing the results to be obtained within second or minutes, instead of hours or days; (vii) improved sensitivity/precision; (viii) versatile and controllable processing of the microfluidic systems at dimensions from micrometers to nanometers; and (ix) widely applicable building materials including plastic to produce microfluidic systems at very low unit cost, allowing them to be disposable and avoiding any type of cross-contamination [17-19].

3. Microfluidic technology for pharmaceutical applications

From the pharmaceutical applications point of view, microfluidic systems offer a better representation of the realistic physiological and pathological conditions of complex systems for both fundamental research and drug development comparatively to conventional macroscale *in vitro* assays that continue to give misleading and non-predictive data for *in vivo* response (Nguyen et al., 2013, Vladisavljevic et al., 2013). In fact, microfluidic systems allow to model biological environments and physically mimic the complex cell-cell and cell-microenvironment interactions found in biological tissue and organs (such as liver, lung, gastrointestinal tract, kidney and heart), usually referred as “organ-on-a-chip” (Caplin et al., 2015, Kolahchi et al., 2016, Zheng et al., 2016a) or at least some of the physiologically relevant processes related to the so-called ADME (adsorption, distribution, metabolism and elimination) processes in the body, which have important role in expediting early stages of drug discovery and help to bypass animal testing (Neuzil et al., 2012, Lee and Sung, 2013). This is because microfluidic systems can provide a precise control of the fluidic microenvironment, which is particularly relevant and representative, as many important biological processes in cells and other biological entities take place and have sizes at the micrometer scale, matching microfluidic channels dimensions (Figure 4).



Figure 4: LOC technologies as tools at molecular and cellular scale (Nguyen et al., 2013).

Fluid flows are an important part of both healthy and pathological conditions, including not only the more obvious flow of blood and lymph in the circulatory system, but also the interstitial flow of blood in nearly all soft tissues. The accurate manipulation of fluid flows in microfluidic systems, with high surface area-to-volume (SAV) ratio, allows to replicate blood circulation in three-dimensional (3D) microenvironments, with microvascular perfusion and diffusion between mimicked microvessels and 3D cell culture providing a continuous supply of nutrients and oxygen, which is closer to what cells encounter in real tissues or organs, alleviating the translational barrier to *in vivo* expectations (Chi et al., 2016, Zheng et al., 2003). Moreover, a uniform thermal field and precise temperature control is reached due to the excellent heat transfer properties (Wu et al., 2006, Wu et al., 2010). However, high SAV is also usually associated with high protein adsorption depending mostly on the wetting properties of the microfluidic system (that can be physically important to the cultured cells). To overcome these limitations, specific surface modifications of the microchannels by plasma treatment or coating with specific chemical compounds have been adopted (Wu et al., 2002, Higuchi et al., 2003). Therefore, key aspects of the biological setting include both micrometer structures and properties as well as controlled fluids flow over the spatiotemporal environment, which can be simulated in microfluidic systems. A high degree of architectures and biocompatible materials, well-developed and well-characterized microfabrication technologies, also provide researchers with a large toolbox to produce specific and tailored designs in a reliable and reproducible manner. Another aspect is the fact that real-time monitoring of cells or tissue-specific response using standard microscopy techniques are also possible since microfluidic systems made of transparent materials, such as glass or polymers, can be designed to fit on top of a standard microscope slide (Bjornmalm et al., 2014, Nguyen et al., 2013, Pihl et al., 2005, Wu et al., 2010). Finally, microfluidic system allow to significantly save cell and drug sample volumes from 10 to 1000-fold less than the conventional counterparts, facilitating systematic high-volume testing in various stages of the drug discovery

process that could be prohibitively expensive otherwise since the quantities of tested drugs or cells are normally very limited in pharmaceutical research and development (Chi et al., 2016).
Therefore, with mimicked close-to-*in vivo* microenvironments and organ-on-a-chip designs, 3D microfluidic cell culture systems will increase the *in vitro* drug screening accuracy that in turn would reduce failing rate through clinical trials in the near future and facilitate the development of safer and more effective drugs, namely in terms of controlled and targeted delivery, at a reduced cost (Chi et al., 2016). The next step is to connect various organs-on-a-chip devices in order to create "body-on-a-chip" that will allow to study the effects of drugs not only in individual organs but to simulate the interactions between various organs, providing a more complete and comprehensive analysis which would ultimately revolutionize how drugs are developed (Caplin et al., 2015, Mahler et al., 2016, Esch et al., 2011). Current works on organs-on-a-chip involve intestine-liver (Kimura et al., 2015), liver-kidney (Leclerc et al., 2016), intestine-liver-skin-kidney co-cultures (Maschmeyer et al., 2015) and neurospheres and liver spheroids co-cultures (Materne et al., 2015), among others. Details of different types of organ-on-a-chip, with attention brought to their design, materials, objectives and results are further discussed in section 5.3. or can be found in excellent reviews related to this matter (Esch et al., 2011, Mahler et al., 2016, Caplin et al., 2015, Lee and Sung, 2013). In addition, the unique advantages, compactness and controllability of LOC have allowed the development of implantable smart microfluidic drug delivery systems consisting of a number of biocompatible microscale components that can regulate and monitor the delivery of the right amount of drug into a specific target site. Such microdevices have been developed for the treatment of cancer, cardiovascular disorder, eye and brain diseases, stress and diabetes (Smith et al., 2007, Samad and Kouzani, 2013, Wang et al., 2012).
Important from a technological point of view, microfluidic systems are not only applied for assay development and disease treatment/diagnosis, but also for templating nano- and microparticles during their fabrication for various pharmaceutical applications and, in particular, for drug delivery purposes. Droplet microfluidics with precisely controlled production of droplets to be used as templates for reproducible and scalable particle fabrication allow significant improvements in tuning sizes (with minimal deviation from mean dispersity values), shapes and morphologies of the materials when compared to traditional bulk techniques. Typically, particle fabrication comprises 3 consecutive steps: i) formation of droplets in microfluidic generators, ii) shaping these droplets in specially designed microchannels, and iii) their solidification by chemical, photochemical or physical methods to form final particulate emulsions (Wang et al., 2017). Passive or active droplet generation methods are adopted (Zhu and Wang, 2017) according to the desired design and final application, for production of spherical and non-spherical particles, microcapsules and vesicles of both organic and inorganic origin, based on single and double multi-emulsion templates. The latter are expectedly more challenging to manufacture, due to the requirement of using two-phase systems and their precise control to achieve complex shapes, such as the core-shell design (Ma et al., 2012). On-chip fabrications of drug delivery systems have been recently reported, achieving complexity in drug carriers coupled to their precise size and composition that contribute to better prediction and tuneability in the drug release profiles (Leon et al., 2015).

Efforts for advancing manufacturing and control of drug delivery particulate-based systems are excellently reviewed in (Riahi et al., 2015).

4. Materials and processing techniques

The materials that have been employed for the fabrication of microfluidic systems range from silicon, glass and ceramics, to polymer-based materials that include elastomers, thermosets, thermoplastics and more recently paper. Depending on the application, required function and degree of integration, special attention should be paid on choosing the correct material for the fabrication of the microfluidic system as it determines both the inherent properties of the device and the possible fabrication technologies that can be used (Ren et al., 2013). Characteristics such as flexibility, air permeability, electrical conductivity, solvent compatibility, optical transparency, and biocompatibility may be important when selecting a material (Nge et al., 2013). Another important factor is the cost that must be minimized in order to fabricate cost-effective products and also single-use disposable devices to avoid cross-contamination between essays.

4.1. Silicon and glass

Silicon and glass are typically processed by well-known fabrication methods from the semiconductor industry (Figures 5 and 6) such as bulk micromachining using wet and dry etching, although silicon structures can also be fabricated by surface micromachining (Iliescu et al., 2012). Bulk micromachining produces structures within the substrate, i.e. substrate is selectively etched, using photolithography to transfer a pattern from a mask to the surface. In turn, surface micromachining allows developing structures on the top of the substrate, which means that thin layers of silicon are subsequently deposited using chemical deposition methods. Silicon is transparent to infrared light, but not in the visible spectral range, making fluorescent detection or fluid imaging challenging.

On the other hand, glass is optically transparent and shows low background fluorescent. Further, glass modification chemistries are silanol based, such as for silicon. Favorable properties of silicon and glass come from their thermostability and solvent compatibility. Therefore, nonspecific adsorption can be reduced or cell growth improved through chemical modification of the surface. Nevertheless, the hardness of silicon and glass, the higher cost and time of fabrication, the difficulty to seal the microfluidic structure and to fabricate and integrate functional units, together with the non-gas permeability have prevented their used in many microfluidic applications and motivate the use and development of other materials that can be easily fabricated and are compatible with a broader range of biological applications (Reyes et al., 2002).

4.2. Polymers

Polymers-based microfluidic systems appear as an interesting alternative, in particular for being relatively inexpensive, suitable for mass production processes and adaptable through formulation changes and chemical modification (Becker and Gartner, 2000, Becker and Locascio, 2002). An additional benefit is the wide range

of available polymers that offer a large flexibility in the selection of material with specific properties. According to their physical properties, polymers can be classified into thermosets, elastomers and thermoplastics. Thermosets such as SU-8 are normally stable even at high temperature, resistant to most solvents, highly biocompatible and usually show proper transparency and mechanical properties. SU-8 allows the fabrication of high-aspect ratio and free-standing microstructures using soft-lithography (Abgrall et al., 2007, del Campo and Greiner, 2007). When properly heated and exposed to specific UV light using high-resolution photomasks with an inverse pattern (as the resist is negative), the parts exposed become cross-linked, while the remainder is soluble and removed during development process. Therefore, SU-8 has been often used as structural material for the fabrication of functional units (e.g. microelectromechanical systems) and often as permanent building template for microfluidic systems based on poly(dimethylsiloxane) (PDMS), the most popular elastomer in microfluidics (Figure 5). In the latter case, during the process, generally called replica molding, PDMS liquid prepolymer is cast on photoresist templates, thermally cured at mild temperature (40-70ºC) and peeled off easily due to its low surface tension (Kim et al., 2008). To enclose the obtained open microfluidic channels, PDMS can be bonded reversibly to PDMS, glass or other substrates by simply making contact or irreversibly by using oxygen plasma treatment or a thin mildly cured layer of PDMS as glue.



(a) (b) (c)

Figure 5: PDMS microfluidic chip for cancer cell separator using size-dependent filtration. The PDMS microchannel was produced by replica molding using a SU-8 master mold fabricated by photolithography. (a) Concepts of the microfluidic chip for filtering ultra-low concentrated cancer cells in patient's peritoneal washes; (b) Fabrication process of the microfluidic chip. SU-8 sheet and two-step exposure was used to make a mold of the chip. The two-step exposure was performed to fabricate a precise uneven PDMS channel for cell filtration; (c) Photograph of fabricated microfluidic chip. The main channel and shallow channels had heights of 100 μm and 8 μm, respectively. Bar is 10 mm. Adapted from (Masuda et al., 2013).

PDMS shows very interesting properties for the fabrication of functional units (e.g. valves and pumps) or/and for the fabrication of PDMS microfluidic systems for biotechnological applications (e.g. for long term cell culture, cell screening and biochemical essays in sealed microchannels) that include high biocompatibility, porous matrix allowing permeation of gases, high elasticity and reasonable cost, rapid fabrication and ease of implementation (McDonald and Whitesides, 2002, Sia and Whitesides, 2003). However, the nonspecificity and permeability by hydrophobic molecules into the channels walls due the hydrophobocity of the PDMS

surface along with the water evaporation though channels walls can cause a change in the concentration and composition of the fluid. Several strategies such as chemical surface modification along with using continuous flow, can often be addressed to overcome these issues (Zhou et al., 2010). Regarding thermoplastics, because of their wide use in industry, their processing by thermomolding is well known. In this case, a large number of structures can be produce at high rate and low cost using metal or silicon templates and high temperatures. However, the fabrication of the this kind of templates is time consuming and expensive and therefore is not widely used for prototypes, being excellent for commercial production (Ren et al., 2013). Typical approaches for sealing open microchannels include thermobonding and glue-assisted bonding (Tsao and DeVoe, 2009). Moreover, surface grafting or dynamic coating can be used to modify the surface of thermoplastics and electrodes are easily integrated (Fair, 2007). Thermoplastics show the interesting ability of being reshaped multiple times by reheating, which is appropriate for molding and bonding. Poly(methyl methacrylate) (PMMA), polystyrene (PS), polyethylene terephthalate (PET) and polyvynilchloride (PVC) are typical thermoplastics used for the fabrication of microfluidic systems (Ren et al., 2013). Although thermoplastics show slightly better solvent compatibility than PDMS, they are barely permeable to gases and their rigidity difficult the fabrication of functional units. In turn, although their melting temperatures are high (i.e. over 280 ºC), perfluorinated polymers, such as perfluoroalkoxy (commonly known as Teflon PFA) and fluorinated ethylenepropylene (Teflon FEP), show good gas permeability, enough softness to fabricate functional units, excellent inertness to chemicals and solvents, antifouling, low nonspecific protein adsorption compared to PDMS, cellular compatibility over 5 days and good optical transparency (Nge et al., 2013).

4.3. Paper

Finally, paper is a cellulose-based material recently introduced as a promising substrate for the development of flexible, disposable, biocompatible and low cost microfluidic systems. In addition to generate flow to transport aqueous liquids due to its porosity and hydrophilicity, allowing also further filtering and separation, paper can be chemically modified and conjugated with many biomolecules, including peptides and nucleotides (Nge et al., 2013). Based on these properties, paper-based microfluidic systems have been mainly developed for diagnosis purposes since the white background provides a contrast for color-based detection techniques (Figure 6).



(a) (b) (c)

Figure 6: 3D paper-based microfluidic device that enables vertical flow multi-step assays for the detection of C-reactive protein based on programmed reagent loading. (a) Schematic representation of the paper-based device. The device consists of two layers. The priming and reagent solutions for colorimetric protein and glucose bioassays were preloaded to each reservoir of the top layer. (step 1) The test solutions were loaded to each injection zone of the bottom layer. (step 2) The chemical reactions in folded paper-based 3D microfluidic device through tip-pinch manipulation of the thumb and index fingers. (step 3) Air dry and image readout after unfolding; (b) Paper-based 3D microfluidic devices (i) before and (ii) after wax-impregnating. Hydrophobic patterns could be clearly observed in the back view after wax-impregnating. Scale bar = 10 mm; (c) Colorimetric bioassays and intensity analyses of glucose concentrations with three image readout instruments. Calibration curves for glucose concentrations of 0–50 mM were $R^2 = 0.9781$ for the scanner, 0.9686 for the microscope, and 0.9658 for the smartphone, respectively. Adapted from (Choi et al., 2015).

Based on the results obtained in this field, it is believed that paper could provide an advantageous platform for accomplishing *in vitro* pre-compound screenings steps, offering a solution to many economical obstacles inherent in the pharmaceutical industry (Chen et al., 2015). Therefore, it is shown that a large set of materials and processing technologies are currently available for microfluidic system development, and new ones are emerging at a rapid rate. Nevertheless, although different materials can be modified or combined to fabricate powerful devices for specific applications, current trends demonstrate that for laboratory research, the proper selection of materials typically implies ease in prototyping and high performance of the system, while in industry, the major concerns rely on the cost of production and the reliability in use (Ren et al., 2013).

5. Representative applications

During the last decade, a significant amount of studies have emerged taking advantage of the characteristics of microfluidic systems for simple sample handling, reagent mixing, separation and detection of the complex biological environments. Along with this, recent improvements in fabrication techniques allow the manipulation of difficult samples and reagents, while still reducing overall costs. Important for pharmaceutical testing, modern microfluidic devices require between 0.1 and 10 µL of sample, significantly decreasing sample and waste volumes. Initial attempts are already carried out to industrialize the fabrication and design of parallel flow of several fluids, meaning multiple samples scanning on a single and portable device. In addition, recent technological advances in material science led to even more obvious reasons for pursuing microfluidics for

pharmaceutical applications. Indeed, fabrication of microfluidic systems on plastic or paper materials allows for mass production at low costs, and these devices can even be disposable. Meanwhile, the investigation towards optimizing designs for high throughput screening multiple assays will considerably reduce time and human effort compared to standard *in vitro* and *in vivo* analysis. Meanwhile, additional investigations are still necessary for confirming the credibility of highly complex LOC capable of sampling, processing, separation, detection and waste handling on a single chip. Such fast and continuous progress makes of microfluidics the technology of choice for future drug discovery/development, pharmacokinetic evaluations and toxicity screenings, drug delivery, diagnostics, and lately, developing of in vitro 3D and whole body models for analysis. To this end, this section is aimed to present some of the most representative examples of microfluidic systems for pharmaceutical investigations, from of commercialized simple LOC devices to novel, highly complex miniaturized designs.

5.1. Microfluidic technology for drug development, drug delivery and diagnostics

5.1.1. Protein expression and enzyme activity/kinetics

Gaining deeper insights of relevant targets for drugs, such as membrane proteins and enzymes, is of paramount importance for advances in pharmaceutical concepts, which will also lead to better understanding the effects of drugs on biological systems and to profile the effects on the metabolic pathways level (Overington et al., 2006). Thus, the development of microfluidic devices for cell-free screening is of particular importance in drug discovery for a clear in vitro view on drug-target effects. One such study aims to significantly reduce consumption of reagents in drug discovery by the development of a strategy for parallel high-throughput modules for cell-free expression of functional cell proteins (Khnouf et al., 2010). The disposable device is compatible with 96-well microliter plate readouts and couples a reaction microchamber with adjacent loading ports and the feeding chamber. The tested membrane-associated proteins were bacteriorhodopsin and apolipoprotein A, both expressed in a single reaction, whereas soluble luciferase and β-lactamase were also co-synthesized.

Related to advances in drug-target research and early-stage toxicity screens, the information of kinetic data on the reaction of enzymes with small molecules are gaining significance for drug discovery and development (Matosevic et al., 2011). Here, the additional challenge that the developed microfluidic platforms has to meet is the rapid (within minutes) determination of enzyme activity and automated measuring (Hughes and Herr, 2010). To do so, enzymes are typically immobilized on solid supports in microchannels that are subjected to a continuous flow of reagents. The same design is also employed for determination of enzyme inhibition in microchannels, this time from the generated fluorescence data. Of especial relevance is that the results in a microfluidic approach are obtained after just 2 minutes, compared to 15 minutes necessary for the same data in the standard plate approach (Garcia et al., 2007).

5.1.2. Diagnostics

Although of secondary interest for the pharmaceutical industry, there is a strong focus in developing microfluidic systems for early diagnosis, particularly relevant for difficult to treat diseases and conditions, e.g. malignant tumors or nosocomial infections. Together with their simplicity and improved diagnostic speed compared to time consuming off-site laboratory tests, microfluidic devices are being developed aiming at better sensitivity and portability. As example is the development of compact disk-based microfluidic systems able to automatize biochemical assays and immunoassays that are eliminating human errors and allow minute reagent consumption during detection (Lai et al., 2004). The type of samples for testing and their collection is not affected by the device design due to the fact that the sample collection remains external, as in the case of any other testing. Examples of the device fabrication range from simple microfluidic immunoassays for rapid saliva-based clinical diagnostics (Herr et al., 2007) to simultaneous multi-detection of hepatitis B, hepatitis C and HIV biomarkers in blood serum (Klostranec et al., 2007). In line with the latter, research focus is directed to develop point-of-care testing devices for infectious diseases (in particular HIV), of paramount interest for public health (Figure 7) (Moon et al., 2009, Lee et al., 2010).



Figure 7: Imaging platform for detection captured cells with a disposable microfluidic device. (a) When light is incident on the captured cells, cells diffract and transmit light. Shadows of the captured lymphocytes generated by diffraction can be imaged by the device in 1 second. Image is obtained with the lensless imaging platform. (b) Photograph of the microfluidic chip and the imaging platform. The entire microfluidic device can be imaged without alignment by simply placing the microfluidic channel on the sensor. (c) Image taken with the imaging platform and the shadow image of the cell in the microfluidic channel is shown. The image is obtained by diffraction. Scale bar = 100 µm. Adapted from (Moon et al., 2009).

Regardless of the sample, multimodal detection is of specific interest for developing competitive immunoassays and simultaneous detection of biomarkers with preference of measuring their fluorescence signals. Nevertheless, label-free immunoassays are also being conducted in microfluidic systems thanks to the coupling with robust and sensitive detection methods, such as surface plasmon resonance (Lee et al., 2007a) and imaging ellipsometry (Wang et al., 2006), generating consistent results with widely accepted ELISA tools. One of the newest paradigms in cancer diagnosis and treatment are exosomes, released from both normal and

cancer cells, however with a different footprint and role in remote cell-to-cell communication and signaling (Tetta et al., 2013). These large extracellular vesicles could serve as carriers for bioactive proteins and different RNA molecules, which means involvement in tumor progression, metastasis and even drug resistance mechanisms (Azmi et al., 2013, Suchorska and Lach, 2016). In this context, an initial tumor could be detected by identifying exposing exosomes in related body fluids (e.g. sputum, blood, serum), released at a very early step in tumor progression. Logically, they became not only targets for new drug discovery and development, but also biomarkers for the diagnosis of cancer, or even seen as transport vehicles for drug delivery (Nazarenko, 2010, Alvarez-Erviti et al., 2011). Thus, exosomes are being targeted by future microfluidic systems that should feature design and dimensions accommodated to the size of these vehicles. The use up to date is still in its infancy and concerns replacement of processes of ultrafiltration and/or ultracentrifugation for isolation of exosomes from cell culture supernatants. The traditional centrifugation protocols are limited to isolation based on size of bioentities and cannot distinguish between different exosomes, those from healthy cells and those from tumor. By using microfluidic channels with especial patterns, similar to that used to isolate rare circulating tumor cells from blood (Stott et al., 2010) and similar dimensions to small vesicles, it is anticipated that such shortcoming might be resolved that will allow improved handling, analysis and manipulation of exosomes. Overall, a broader use of microfluidic platforms is yet to be established in diagnostics, both as reliable point-of-care home/clinical devices and separation/purification tools.

5.1.3. Microfluidic high-throughput screening

Systematic screens and large data processing became an integral part of pharmaceutical research that facilitates the evaluation of complex reactions, interactions and systems. Systematic screens are useful to resolve massive data for chemical (Einav et al., 2008), biochemical (Maerkl and Quake, 2007) and cell based assays (Gomez-Sjoberg et al., 2007). Since global screens in pharmacy lead to improved reliability of the developed treatments, today's existing libraries are counting up to tens of thousands of elements. Microfluidic based systematic screens are likely to be more frequently used in the near future. First progress were achieved by Caliper Life Sciences with their generic platform employed for various types of high throughput screening (HTS) applications (Potera, 2005). Its primary use is carrying out enzymatic assays on a glass microchip with integrated capillaries that drag examination fluids from plate wells, at the same time continuously drawing enzyme and substrates from wells-integrated on-chip. The mixtures are transported in a microchannel to a detection point where fluorescence readout is performed. The chips can transport a large number of examination fluids, intercalated with buffer flushing steps to clean the system between the readings. This microfluidic network is capable of assaying with considerably higher throughput and significantly less consumption than conventional plate-based screening devices. The platform is currently used in a large number of pharmaceutical companies in HTS applications.

5.2. Cell-based devices

5.2.1. Simple cell-based devices

LOC technology is nowadays being increasingly investigated for developing *in vitro* models of different diseases/conditions or for carrying out more predictive toxicity studies. Due to the nature of biological systems, of particular interest are cell-based models, both single-cell arrays and complex 3D cell culture systems. In *in vitro* models, cell type and source are the key factors influencing accurate representation of the (patho)physiological states found *in vivo*, and thus reliability and validity of *in vitro* studies. To date, successful examples include primary cells of liver, heart and brain, among others. However, culturing of primary cells usually results in a reduction in specificity due to important alterations of the environment in cell culture vessels (Beigel et al., 2008). The current choice of microfluidic systems is owed to better mimicking the cellular microenvironment and improved cell handling, positioning and analysis. Nevertheless, some challenges still remain, such as poor small-volume liquid handling ability, large consumption of reagents and high cost of operation. Liu et al. (Liu et al., 2008) suggested an integration of combinatorial mixer to 3D microfluidic device able to culture and screen the combinatorial effects of multiple compound exposure on cultured cells. A 1 cm × 1 cm chip with a three-input combinatorial mixer and eight individually isolated microculture chambers was fabricated to proof the concept (Figure 8).



Figure 8: Microfluidic multiple cell culture array with an integrated combinatorial mixer. (a) Fabricated 1 cm × 1 cm chip. (b) SEM image of the cross-section of the microfluidic overpass. The overpass has two-level microfluidic channels and such structures allow that two fluidic streams are separated spatially at the overpass. (c) Surface height profile scan of the overpass region. The overpass structure is about 15–20 μm higher than the first-level microfluidic channels. Reproduced from (Liu et al., 2008).

Of particular importance is culturing stem cells in microfluidic platforms, since nowadays adopted cell isolation and culturing techniques are not able to predictively direct their differentiation towards relevant cell types in order to produce *in vitro* models of e.g. disease for drug-target evaluation or toxicity studies (Rubin and Haston, 2011). Microfluidic assays appear as alternatives for cell fate *in vitro* control by improving the spatiotemporal cell behavior, especially due to better control of biochemical and biophysical extracellular factors (Kobel and Lutolf, 2011, Edalat et al., 2012). Nevertheless, the development of such platforms is still

in its infancy, and more intensive focus to such investigations is necessary to propose an optimal design to control cell fate by environmental factors.

One important application of microfluidic cell culture systems is analysis of DNA damage in cancer models, an alternative to the widely accepted multi-step comet electrophoresis assay, which analyses damage and repair on a single-cell level. A microwell array patterned in an agarose layer of Wood *et al.* (Wood et al., 2010) allows single-cell trapping and high-throughput analysis of DNA damage, but also overcomes impeded cell analysis because of overlapping cells. The device is fully automated and enables analysis of captured in microwells single cells in a single focal plane (and not overlapping). The technology is transferable to study DNA damage or drug screening in a high throughput, because the micropatterned array (microwells) can be sandwiched between a substrate and a microliter plate. Another noteworthy development is in droplet technology for drug discovery, which further elaborates encapsulation of single cells within droplets being again compatible with high-throughput screening and cell sorting (Baret et al., 2009). For example, a droplet viability assay that allows the quantitative scoring of cell viability was developed to allow screening of drug libraries for cytotoxic effects on cells (Brouzes et al., 2009). A cell-containing droplet is combined with a fluorescently encoded one and with varied concentrations of drug, whereas the system enables their incubation during ~15 minutes before analyzing cell viability.

5.2.2. Toxicity

In case of toxicity evaluation, the information obtained from these models serves to predict the safety aspects of the potential drug candidates, where absorption, distribution, metabolism, elimination and toxicity properties are evaluated. Accordingly, the undesirable toxicity of drug is nowadays a leading cause of drug development failures (Kramer et al., 2007). The established assays for cytotoxicity, genotoxicity, drug-drug interactions and metabolite-mediated toxicity are microplate- and micronucleus-based ones. These evaluations are also possible to be carry out in microfluidic platforms (Du et al., 2006, Miller and Wheeler, 2008, Perrin et al., 2006). Similar designs were used to go beyond evaluation of toxicity in cells/organs, to reconstitute the metabolism of a drug and to evaluate systemic responses in *in vitro* models. The provided pharmacokinetic information for early toxicity evolved into a holistic view of toxicology *in vitro*, to be carried out prior to more expensive *in vivo* investigations. One example it to evolve from cell culture analogue (Sweeney et al., 1995) to a microscaled 'animal-on-a-chip' system that integrates co-cultures of different tissues and fat cells with physiological fluid arrays on a single chip (Viravaidya et al., 2004, Viravaidya and Shuler, 2004). The chip is a model to create a surrogative predictor of animal experiments for chemical exposure assessment, something only achievable with time-consuming and costly multiple conventional toxicity studies. This chip represent a step closer to progresses that will enable robust *in vitro* toxicology models for testing pharmacokinetic profiles of drugs and systemic toxicity specific to humans, instead of animals (Yang et al., 2008). Of course, for the viable adoption in pharma, both high-throughput and high content assays must be conductible, which means properly designed and integrated microfluidic set-up. Additionally, research and development efforts should

also be directed to microfluidic systems for functional 3D cell cultures.

5.2.3. Three-dimensional cell culture

Growing cells in 3D brings about several advantages to flat layer culturing: i) altered cell morphology, ii) a more realistic drug response due to increased resistance, iii) captured phenotypic heterogeneity, and iv) mimic of the tumor environment. Also, in addition to controversies related to *in vivo* testing, many cancer still lack qualified animal models. Compared to flat cell layers, 3D cultured cells more closely resemble cell-cell interactions and tumor heterogeneities *in vivo* (Abbott, 2003). On the minus side, 3D cell elaboration is more complicated and costly than already adopted and reasonably reliable monolayer cultures. Nevertheless, new developments in chip technologies and microfluidic platforms are now paving the way for more feasible and affordable 3D cell cultures and experiments.

For example, micropatterned substrates can be used to precisely control the size and shape of the multicellular aggregates (microtissues), which enables the optimal supply of nutrients to cells and the removal of undesired metabolites. In this context, it is particularly interesting the fabrication of temperature-responsive microarrays for the formation of artificial tissue of controlled size and shape as tissue models for drug discovery (Tekin et al., 2011). Thus, temperature-responsive poly(*N*-isopropylacrylamide) polymer micropatterns provides reversible states of cell-adherent (37 ºC) and cell-repellent (24 °C) behavior. Alternatively, microtissues can be processed in microfluidic devices via photo-encapsulation of up to 1000 cells in polyethylene-glycol hydrogels, so that the microtissues could be studied with a multiplexed microfluidic approach (Chen et al., 2010). The mechanically stabilized microtissues of 250-350 µm have been used in high-throughput flow sorting and analysis, as example of quantitative statistical analysis. On the other hand, strategies using continuous-flow lithographic encoding can be used in similar methods as attempt to improve multiplexing capabilities (Pregibon et al., 2007). Such attempts are directed to standardization of high-throughput tests to evaluate the response of 3D models to different drugs and their combinations. In light with the aforementioned, new microfluidic platforms provided with increased functionality are developed to improve data quality from *in vitro* assays (Freytes et al., 2009, Kobel and Lutolf, 2010). However, besides providing deeper insight into the spatiotemporal cues that govern cell fates, the key point is to turn these platforms into high-throughput devices with sufficient accuracy for drug discovery platforms. Chi et al. excellently reviewed how the scientific advances turned out into more matured 3D bio-microfabrication technologies and exemplified several companies offering chips for reliable biochemical assays, cell/biomarker and infectious disease diagnostics, 3D models for drug discovery, screening, and delivery (Chi et al., 2016).

5.3. Organs-on-a-chip, a step towards whole body models

5.3.1. Organs-on-a-chip

Going beyond cell-cell interactions in 3D chip models, efforts are being carried out to optimize fabrication of microfluidic devices that combine several cell types in 2D or 3D designs in order to simulate human organs on a single chip (van Midwoud et al., 2010, van Midwoud et al., 2011). Such chips resemble more closely complex interactions between different tissues and organs, in contrast to mimicking interactions between cells of the same type in 3D models (Zheng et al., 2016b). Thus, these systems hold enormous potential to reduce or even completely replace animal testing because they circumvent the major limitation of *in vivo* tests, i.e. metabolic differences between humans and animals. It is expected that the obtained information on drug efficacy and toxicity on an organ level will allow more accurate early-phase decisions in future drug development.

From a technological point-of-view and in order to successfully simulate tissue-tissue interactions, a model with different cell types cultured in 3D designs but using separate chambers is proposed, where the microtissues were connected by a microfluidic network (Sung and Shuler, 2009). The connective network allows for reproduction of the pharmacokinetic profiles of drugs simultaneously in cancerous and healthy tissues, which were by far different to the effects observed in a conventional microplate assay. It is worth mentioning that additional experimentation should be made for adjusting tissue geometries and channel profiles so that fluid residence times correspond to physiological residence times of body fluids in the targeted organs. In a similar approach, a compartmental design has been proven to be successful for fabrication of a bi-layer silicone microfluidic structure, aimed to mimic alveolar-capillary interface of a human lung while integrating mechanical cell actuation (Huh et al., 2010). The mechanical actuation was simulated by applying vacuum at the separate ends of a middle channel with cultured human alveolar epithelial cells in air on the upper side, whereas the lower channel contained a fluid with vascular endothelial cells. The resulting stretching of the silicone membrane enhanced cellular uptake of nanoparticles, influencing inflammatory responses similarly as in *in vivo* studies. In a more complex approach, the reconstitution of a small artery on a microfluidic chip was achieved by Günther *et al.* (Gunther et al., 2010). A triple microchannel systems for the fixation, perfusion and superfusion of the vessel was used for long-term culture and investigation under the influence of phenylephrine or acetylcholine. This system may thus present a ground-breaking achievement for enabling pharmacological and toxicological screens and evaluate the effect of new drugs in arteries. Readers are further encouraged to search the references from Table 1, containing some of the most relevant examples of organs-on-a-chip.

Table 1: Examples for organs-on-a-chip for drug testing and delivery.

Model organ	Experimental model	Means of testing	References

Heart	Anisotropic cardiac microtissues and soft elastomers in thin film	Effect of isoproterenol on cardiac contractility	(Agarwal et al., 2013)
	Micromolded gelatin hydrogel	Cell metabolic function over four weeks for chronic studies	(McCain et al., 2014)
Liver	Microfluidic endothelial-like barrier of hepatocytes	Effect of diclofenac on hepatotoxicity	(Lee et al., 2007b)
	Multiplexed microfluidic channels each one with 3D microenvironment	Five model drugs for dose-dependent on-chip testing	(Toh et al., 2009)
Lung	Two microchannels one with epithelial cells and other with endothelial cells, separated by a poly(dimethylsiloxane) membrane	Organ-level responses to bacteria, inflammatory cytokines and silica nanoparticles	(Huh et al., 2010)
	Two side channels for vacuum-mimic breathing	Effect of several drugs for prevention of interleukin-2 induced pulmonary edema	(Huh et al., 2012)
Brain	Microfabricated low-stress silicon nitride membranes	In vitro model of blood-brain barrier based on the effect of protein treatments to cell seeding	(Harris and Shuler, 2003)
	Molded transparent polymers in a multi-compartment cell culture platforms	Culturing neurons of central and peripheral nervous systems	(Park et al., 2006)
Kidney	Multi-layer device integrating polydimethyl siloxane microfluidic channel and a porous membrane	Culturing and analysis of renal cells while mimicking tubular-like stress environments	(Jang and Suh, 2010)
	Extracellular matrix-coated polyester membrane separating main channel into luminal and interstitial space	Albumin transport, glucose reabsorption and brush border alkaline phosphatase activity in epithelial cells	(Jang et al., 2013)
Intestine	Two channels separated by a semipermeable membrane for cell inoculation and culturing	Long-term (2 weeks) culture and monitoring of polarized transport activity of Caco-2	(Kimura et al., 2008)

		cells	
	Same as above with co-cultured epithelial cells and normal intestinal microbe	Tests for mimicking complex structure and physiology of living intestine	(Kim et al., 2012)
Blood vessels	Litography-engineered microvascular networks in 3D collagen scaffold	Characterization of morphology, mass transfer processes and long-term stability of the endothelium	(Zheng et al., 2012)
	Soft-litographic definition of triple microchannel network of poly(dimethylsiloxane) on a single plane	Smooth muscle and endothelial function and investigation under the influence of phenylephrine or acetylcholine	(Gunther et al., 2010)

Besides toxicological response in 3D model platforms comprised of healthy cells to mimic human organs, modeling microfluidic platforms that resemble *in vivo* cancerous situations is of especial interest for pharmacological monitoring of drug effects. So called tumors-on-a-chip are models aimed to screen behavior of cancer cells, e.g. antiangiogenesis, during the treatment with drugs, investigate interaction between healthy and tumor cells, or focus on improving the detection of cancer at the disease onset. For the latter, microfluidic devices are designed with lateral channel structures in which circulating tumor cells or relevant biomarkers in small concentrations are collected and quantified (Hyun et al., 2013, Li et al., 2013). More complex structures are necessary to be developed for detailed recapitulation of tumor microenvironments, such as recently developed *in vitro* model with 3D structure of microfluidic channels where tumor cells and endothelial cells are cultured within extracellular matrix under perfusion of interstitial fluid (Kwak et al., 2014). The system allows simulation of complex drug transport around the tumor and is tested with nanoparticulate-based therapeutic agents aiming targeted delivery of therapy. The information obtained from this tumor-microenvironment-on-chip model is particularly relevant as it provides guidance for design of nanoparticles (including perception about optimal size and morphology) in the associated therapeutic approaches.

Although the principles for developing tumor models or hybrid tumor models (comprising both tumor and healthy cells) are similar for different cancer types, only individual investigations on each particular model can give specifics regarding effectiveness of therapeutic approaches, regardless of their nature. Thus, it is of paramount importance that the microenvironments of specific tumors are matched in those models. Studies are continuously reported, while here we highlight the progresses in the development of lung (Xu et al., 2013, Huang et al., 2014), breast (Sung et al., 2011), prostate (Augustsson et al., 2012, Chiriaco et al., 2013),

pancreas (Kamande et al., 2013) and brain (Khan and Vanapalli, 2013) cancer models, for various purposes in cancer research.

5.3.2. Multiple organs-on-a-chip

A further step towards ultimate realistic investigation models, but also towards complexity, is culturing multiple organs-on-a-chip (Figure 9) (Jackson and Lu, 2016, Esch et al., 2014, Wikswo et al., 2013). Particularly challenging for providing reliability in these authentic whole-body-on-a-chip systems is the necessary allometric scaling effect of the micro-organs. Thus, scaling must involve mass allometrics of the organs, coupled to mimicking different blood circulation and pulse through the organs. In addition, the preservation of the important organ functions is paramount during scaling, all connected to raising challenges of the microfluidic design. Finally, interconnecting of organs-on-a-chip should follow the real interaction of organs in humans, i.e. which organs must interact with others and which must not come into contact with the common medium. The common medium must be "friendly" for all cells in the model.



Figure 9: The human-on-a-chip concept. Biomimetic microsystems representing different organs can be integrated into a single microdevice and linked by a microfluidic circulatory system in a physiologically relevant manner to model a complex, dynamic process of drug absorption, distribution, metabolism and excretion, and to more reliably evaluate drug efficacy and toxicity. As shown in this example, an integrated system of microengineered organ mimics (lung, heart, gut, liver, kidney and bone) can be used to study the absorption of inhaled aerosol drugs (red) from the lung to microcirculation, as well as to measure their

cardiotoxicity (e.g. changes in heart contractility or conduction), transport and clearance in the kidney, metabolism in the liver, and immune-cell contributions to these responses. Drug substances (blue) also can be introduced into the gut compartment to investigate interplay between orally administered drugs and molecular transporters and metabolizing enzymes expressed in the various organs (Huh et al., 2011).

As a stand out work on a multi-channel 3D system integrating micro-organs of liver, lung, kidney and fat tissue was presented by Zhang et al. (Zhang et al., 2009). A common medium was maintaining the functions of four different cell lines (i.e. micro-organs), coming from one reservoir with connections to an inlet directly attached to each cell group. Such design enables testing the multi-organ implications in drug delivery and toxicity. In an ideal scenario (without a drug), all cells were able to function above 90% of their usual activity. When tested with a growth factor, growth was promoted in three out of four cell lines, with a significantly lower viability of the fourth line. In a further experiment involving protein microspheres to control the growth factor release into only one cell line group, the results showed that it is possible to selectively stimulate one particular cell line without adverse effects to other cells.
Another multiple organs-on-a-chip was designed to test drug toxicity in three different cell lines separated in three culture chambers, which enabled mapping drug pharmacological effects (Sung et al., 2010). The device was tested with healthy liver cells, colon tumor cells and leukemic cells. A reservoir containing suitable medium was connected to the three cell culture chambers, whereas the medium flow rate was controlled by gravity. An anticancer drug was used for testing, showing a decline in viability between all three cell groups.
Besides culturing tissues and multiple organs, microfluidic devices are increasingly investigated for improved screening and data synthesis of animal organisms. Small vertebrates are very useful in drug discovery for testing on a systemic level, however with conventional methods the testing is usually highly complex, dependent on many low controllable factors and time-consuming. Automated microscopy (Conrad et al., 2011) and especially microfluidics are significantly simplifying and accelerating the testing. Microfluidic platforms simplify the handling, positioning, orienting and manipulating of the entire organisms and analyses, proven on different organisms, such as not parasitic worms (Hulme et al., 2010) embryos of a fly (Chung et al., 2011, Ghaemi and Selvaganapathy, 2016) or zebrafish (Pardo-Martin et al., 2010). Exemplified, microfluidic arrays are able to order and vertically orient e.g. fly embryos on a large scale to enable quantitative imaging of the embryos in a position not possible with traditional coverslip-based approaches. A microscale meandering manifold injects and transports the embryos to intersections with cross-flow channels where the similar in size embryos are vertically trapped in a cylindrical cut-out controlled by the injection pressure. Then, the embryos can be securely transported in the orientation essential for high-throughput screening systems, for example to allow quantitative analysis of different patterns within the biosystem (Chung et al., 2011). The model was also successfully translated to high-throughput assays and monitoring developmental responses of embryos to external stimuli (Levario et al., 2016). Another example is a high-throughput system for automated investigations, proven for chemical and genetic screening of zebrafish larvae

(Pardo-Martin et al., 2010). All steps of the system were automated, from loading the larvae, optical detection, positioning and rotation in a rotatable capillary, image focusing and acquisition, laser manipulation and dispensing step back into a multiwell plate. The system is able to provide confocal imaging and laser-based microsurgery of oriented zebrafish larvae within less than twenty seconds, and set the basis for similar investigations (Deveau et al., 2017, Liu et al., 2016).

6. Summary and outlook

An overview of the main topics related to microfluidics for pharmaceutical applications has been provided demonstrating the technological ability to miniaturize many larger scale complex processes and giving rise to the LOC concept.

With respect to pharmaceutical applications, microfluidic systems, together with the inherent advantages of miniaturization, low-cost, fast processing and low sample quantity, allow to obtain high-quality, high-throughput data, which is particularly relevant for drug development and testing. Microfluidics-based drug testing platforms allow evaluating time-dependent dynamics, toxicity and multi-cell interactions. Thus, not only performance and eventual side effects of drugs are detected, but also allow evaluating the underlying mechanisms of drug response. Particularly interesting is the mimicking of the *in vivo* microenvironments and the organ-on-a-chip approach that will, eventually, lead to realistically mimic characteristics and functionality of a whole-body response. This will represent a major breakthrough not only in the pharmaceutical area, but in the whole biomedical field.

Finally, it has been shown that the major future trends and needs in this field are the development of high performance microscale research and development platforms as well as the fabrication of low-cost, portable analysis systems. In this context, a strong interdisciplinary approach is needed, ranging from the essential knowledge of the physical-chemical aspect of materials and processes to the development of suitable materials and production technologies, taken into account the biomedical aspects of the final application. All this together will allow overcoming the present limitations and needs of these microtechnologies with huge macro implications.

Acknowledgements

The authors thank the FCT - Fundação para a Ciência e Tecnologia - for financial support under framework of the Strategic Funding UID/FIS/04650/2013, project PTDC/EEI-SII/5582/2014 and project UID/EEA/04436/2013 by FEDER funds through the COMPETE 2020 – Programa Operacional Competitividade e Internacionalização (POCI) with the reference project POCI-01-0145-FEDER-006941. Funds provided by FCT in the framework of EuroNanoMed 2016 call, Project LungChek (ENMed/0049/2016)

are also gratefully acknowledged. VFC and AF also thank the FCT for the post-doctoral grants SFRH/BPD/98109/2013 and SFRH/BPD/104204/2014, respectively. Finally, the authors acknowledge funding by the Spanish Ministry of Economy and Competitiveness (MINECO) through the project MAT2016-76039-C4-3-R (AEI/FEDER, UE) and from the Basque Government Industry Department under the ELKARTEK program.

References

ABBOTT, A. 2003. Cell culture: Biology's new dimension. *Nature,* 424**,** 870-872.

ABGRALL, P., CONEDERA, V., CAMON, H., GUE, A. M. & NGUYEN, N. T. 2007. SU-8 as a structural material for labs-on-chips and microelectromechanical systems. *Electrophoresis,* 28**,** 4539-4551.

AGARWAL, A., GOSS, J. A., CHO, A., MCCAIN, M. L. & PARKER, K. K. 2013. Microfluidic heart on a chip for higher throughput pharmacological studies. *Lab on a Chip,* 13**,** 3599-3608.

ALVAREZ-ERVITI, L., SEOW, Y. Q., YIN, H. F., BETTS, C., LAKHAL, S. & WOOD, M. J. A. 2011. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nature Biotechnology,* 29**,** 341-U179.

AUGUSTSSON, P., MAGNUSSON, C., NORDIN, M., LILJA, H. & LAURELL, T. 2012. Microfluidic, Label-Free Enrichment of Prostate Cancer Cells in Blood Based on Acoustophoresis. *Analytical Chemistry,* 84**,** 7954-7962.

AZMI, A. S., BAO, B. & SARKAR, F. H. 2013. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. *Cancer and Metastasis Reviews,* 32**,** 623-642.

BARET, J. C., MILLER, O. J., TALY, V., RYCKELYNCK, M., EL-HARRAK, A., FRENZ, L., RICK, C., SAMUELS, M. L., HUTCHISON, J. B., AGRESTI, J. J., LINK, D. R., WEITZ, D. A. & GRIFFITHS, A. D. 2009. Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity. *Lab on a Chip,* 9**,** 1850-1858.

BECKER, H. & GARTNER, C. 2000. Polymer microfabrication methods for microfluidic analytical applications. *Electrophoresis,* 21**,** 12-26.

BECKER, H. & LOCASCIO, L. E. 2002. Polymer microfluidic devices. *Talanta,* 56**,** 267-287.

BEIGEL, J., FELLA, K., KRAMER, P. J., KROEGER, M. & HEWITT, P. 2008. Genomics and proteomics analysis of cultured primary rat hepatocytes. *Toxicology in Vitro,* 22**,** 171-181.

BJORNMALM, M., YAN, Y. & CARUSO, F. 2014. Engineering and evaluating drug delivery particles in microfluidic devices. *Journal of Controlled Release,* 190**,** 139-149.

BRASK, A., KUTTER, J. P. & BRUUS, H. 2005. Long-term stable electroosmotic pump with ion exchange membranes. *Lab on a Chip,* 5**,** 730-738.

BRODY, J. P., YAGER, P., GOLDSTEIN, R. E. & AUSTIN, R. H. 1996. Biotechnology at low Reynolds numbers. *Biophysical Journal,* 71**,** 3430-3441.

BROUZES, E., MEDKOVA, M., SAVENELLI, N., MARRAN, D., TWARDOWSKI, M., HUTCHISON, J. B., ROTHBERG, J. M., LINK, D. R., PERRIMON, N. & SAMUELS, M. L. 2009. Droplet microfluidic technology for single-cell high-throughput screening. *Proceedings of the National Academy of Sciences of the United States of America,* 106**,** 14195-14200.

BYUN, C. K., ABI-SAMRA, K., CHO, Y. K. & TAKAYAMA, S. 2014. Pumps for microfluidic cell culture. *Electrophoresis,* 35**,** 245-257.

CAPLIN, J. D., GRANADOS, N. G., JAMES, M. R., MONTAZAMI, R. & HASHEMI, N. 2015. Microfluidic Organ-on-a-Chip Technology for Advancement of Drug Development and Toxicology. *Advanced Healthcare Materials,* 4**,** 1426-1450.

CAPRETTO, L., CHENG, W., HILL, M. & ZHANG, X. 2011. Micromixing Within Microfluidic Devices. *In:* LIN, B. C. (ed.) *Microfluidics: Technologies and Applications.*

CARDOSO, V. F., KNOLL, T., VELTEN, T., REBOUTA, L., MENDES, P. M., LANCEROS-MÉNDEZ, S. & MINAS, G. 2014. Polymer-based acoustic streaming for improving mixing and reaction

times in microfluidic applications. *Rsc Advances,* 4, 4292-4300.
CHAO, T.-C. & HANSMEIER, N. 2013. Microfluidic devices for high-throughput proteome analyses. *Proteomics,* 13, 467-479.
CHEN, A. A., UNDERHILL, G. H. & BHATIA, S. N. 2010. Multiplexed, high-throughput analysis of 3D microtissue suspensions. *Integrative Biology,* 2, 517-527.
CHEN, Y.-H., KUO, Z.-K. & CHENG, C.-M. 2015. Paper – a potential platform in pharmaceutical development. *Trends in Biotechnology,* 33, 4-9.
CHI, C. W., AHMED, A. H. R., DERELI-KORKUT, Z. & WANG, S. H. 2016. Microfluidic cell chips for high-throughput drug screening. *Bioanalysis,* 8, 921-937.
CHIN, C. D., LINDER, V. & SIA, S. K. 2007. Lab-on-a-chip devices for global health: Past studies and future opportunities. *Lab on a Chip,* 7, 41-57.
CHIN, C. D., LINDER, V. & SIA, S. K. 2012. Commercialization of microfluidic point-of-care diagnostic devices. *Lab on a Chip,* 12, 2118-2134.
CHIRIACO, M. S., PRIMICERI, E., MONTANARO, A., DE FEO, F., LEONE, L., RINALDI, R. & MARUCCIO, G. 2013. On-chip screening for prostate cancer: an EIS microfluidic platform for contemporary detection of free and total PSA. *Analyst,* 138, 5404-5410.
CHOI, S., KIM, S. K., LEE, G. J. & PARK, H. K. 2015. Paper-based 3D microfluidic device for multiple bioassays. *Sensors and Actuators, B: Chemical,* 219, 245-250.
CHOVAN, T. & GUTTMAN, A. 2002. Microfabricated devices in biotechnology and biochemical processing. *Trends in Biotechnology,* 20, 116-122.
CHUNG, K., KIM, Y., KANODIA, J. S., GONG, E., SHVARTSMAN, S. Y. & LU, H. 2011. A microfluidic array for large-scale ordering and orientation of embryos. *Nature Methods,* 8, 171-U103.
CONRAD, C., WUNSCHE, A., TAN, T. H., BULKESCHER, J., SIECKMANN, F., VERISSIMO, F., EDELSTEIN, A., WALTER, T., LIEBEL, U., PEPPERKOK, R. & ELLENBERG, J. 2011. Micropilot: automation of fluorescence microscopy-based imaging for systems biology. *Nature Methods,* 8, 246-U89.
DEL CAMPO, A. & GREINER, C. 2007. SU-8: a photoresist for high-aspect-ratio and 3D submicron lithography. *Journal of Micromechanics and Microengineering,* 17, R81-R95.
DEVEAU, A. P., BENTLEY, V. L. & BERMAN, J. N. 2017. Using zebrafish models of leukemia to streamline drug screening and discovery. *Experimental Hematology,* 45, 1-9.
DITTRICH, P. S. & MANZ, A. 2006. Lab-on-a-chip: microfluidics in drug discovery. *Nature Reviews Drug Discovery,* 5, 210-218.
DU, W. B., FANG, Q. & FANG, Z. L. 2006. Microfluidic sequential injection analysis in a short capillary. *Analytical Chemistry,* 78, 6404-6410.
EDALAT, F., BAE, H., MANOUCHERI, S., CHA, J. M. & KHADEMHOSSEINI, A. 2012. Engineering Approaches Toward Deconstructing and Controlling the Stem Cell Environment. *Annals of Biomedical Engineering,* 40, 1301-1315.
EINAV, S., GERBER, D., BRYSON, P. D., SKLAN, E. H., ELAZAR, M., MAERKL, S. J., GLENN, J. S. & QUAKE, S. R. 2008. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. *Nature Biotechnology,* 26, 1019-1027.
ESCH, M. B., KING, T. L. & SHULER, M. L. 2011. The Role of Body-on-a-Chip Devices in Drug and Toxicity Studies. *In:* YARMUSH, M. L., DUNCAN, J. S. & GRAY, M. L. (eds.) *Annual Review of Biomedical Engineering, Vol 13.*
ESCH, M. B., SMITH, A. S. T., PROT, J. M., OLEAGA, C., HICKMAN, J. J. & SHULER, M. L. 2014. How multi-organ microdevices can help foster drug development. *Advanced Drug Delivery Reviews,* 69, 158-169.
FAIR, R. B. 2007. Digital microfluidics: is a true lab-on-a-chip possible? *Microfluidics and Nanofluidics,* 3, 245-281.
FLUIDICMEMS. 2016. *List of microfluidics companies* [Online]. Available: http://fluidicmems.com/list-of-microfluidics-lab-on-a-chip-and-biomems-companies/ February 2017].
FREYTES, D. O., WAN, L. Q. & VUNJAK-NOVAKOVIC, G. 2009. Geometry and Force Control of

Cell Function. *Journal of Cellular Biochemistry,* 108, 1047-1058.

GARCIA, E., HASENBANK, M. S., FINLAYSON, B. & YAGER, P. 2007. High-throughput screening of enzyme inhibition using an inhibitor gradient generated in a microchannel. *Lab on a Chip,* 7, 249-255.

GAUDIOSO, J. & CRAIGHEAD, H. G. 2002. Characterizing electroosmotic flow in microfluidic devices. *Journal of Chromatography A,* 971, 249-253.

GHAEMI, R. & SELVAGANAPATHY, P. R. 2016. Microfluidic Devices for Automation of Assays on Drosophila Melanogaster for Applications in Drug Discovery and Biological Studies. *Current Pharmaceutical Biotechnology,* 17, 822-836.

GOMEZ-SJOBERG, R., LEYRAT, A. A., PIRONE, D. M., CHEN, C. S. & QUAKE, S. R. 2007. Versatile, fully automated, microfluidic cell culture system. *Analytical Chemistry,* 79, 8557-8563.

GUNTHER, A., YASOTHARAN, S., VAGAON, A., LOCHOVSKY, C., PINTO, S., YANG, J. L., LAU, C., VOIGTLAENDER-BOLZ, J. & BOLZ, S. S. 2010. A microfluidic platform for probing small artery structure and function. *Lab on a Chip,* 10, 2341-2349.

HARRIS, S. G. & SHULER, M. L. 2003. Growth of endothelial cells on microfabricated silicon nitride membranes for an in vitro model of the blood-brain barrier. *Biotechnology and Bioprocess Engineering,* 8, 246-251.

HERR, A. E., HATCH, A. V., THROCKMORTON, D. J., TRAN, H. M., BRENNAN, J. S., GIANNOBILE, W. V. & SINGH, A. K. 2007. Microfluidic immunoassays as rapid saliva-based clinical diagnostics. *Proceedings of the National Academy of Sciences of the United States of America,* 104, 5268-5273.

HIGUCHI, A., SUGIYAMA, K., YOON, B. O., SAKURAI, M., HARA, M., SUMITA, M., SUGAWARA, S. & SHIRAI, T. 2003. Serum protein adsorption and platelet adhesion on pluronic (TM)-adsorbed polysulfone membranes. *Biomaterials,* 24, 3235-3245.

HUANG, T., JIA, C. P., JUN, Y., SUN, W. J., WANG, W. T., ZHANG, H. L., CONG, H., JING, F. X., MAO, H. J., JIN, Q. H., ZHANG, Z., CHEN, Y. J., LI, G., MAO, G. X. & ZHAO, J. L. 2014. Highly sensitive enumeration of circulating tumor cells in lung cancer patients using a size-based filtration microfluidic chip. *Biosensors & Bioelectronics,* 51, 213-218.

HUGHES, A. J. & HERR, A. E. 2010. Quantitative Enzyme Activity Determination with Zeptomole Sensitivity by Microfluidic Gradient-Gel Zymography. *Analytical Chemistry,* 82, 3803-3811.

HUH, D., HAMILTON, G. A. & INGBER, D. E. 2011. From 3D cell culture to organs-on-chips. *Trends in Cell Biology,* 21, 745-754.

HUH, D., LESLIE, D. C., MATTHEWS, B. D., FRASER, J. P., JUREK, S., HAMILTON, G. A., THORNELOE, K. S., MCALEXANDER, M. A. & INGBER, D. E. 2012. A Human Disease Model of Drug Toxicity-Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice. *Science Translational Medicine,* 4.

HUH, D., MATTHEWS, B. D., MAMMOTO, A., MONTOYA-ZAVALA, M., HSIN, H. Y. & INGBER, D. E. 2010. Reconstituting Organ-Level Lung Functions on a Chip. *Science,* 328, 1662-1668.

HULME, S. E., SHEVKOPLYAS, S. S., MCGUIGAN, A. P., APFELD, J., FONTANA, W. & WHITESIDES, G. M. 2010. Lifespan-on-a-chip: microfluidic chambers for performing lifelong observation of C. elegans. *Lab on a Chip,* 10, 589-597.

HYUN, K. A., LEE, T. Y. & JUNG, H. I. 2013. Negative Enrichment of Circulating Tumor Cells Using a Geometrically Activated Surface Interaction Chip. *Analytical Chemistry,* 85, 4439-4445.

ILIESCU, C., TAYLOR, H., AVRAM, M., MIAO, J. & FRANSSILA, S. 2012. A practical guide for the fabrication of microfluidic devices using glass and silicon. *Biomicrofluidics,* 6.

INAMDAR, N. K. & BORENSTEIN, J. T. 2011. Microfluidic cell culture models for tissue engineering. *Current Opinion in Biotechnology,* 22, 681-689.

JACKSON, E. L. & LU, H. 2016. Three-dimensional models for studying development and disease: moving on from organisms to organs-on-a-chip and organoids. *Integrative Biology,* 8, 672-683.

JANG, K. J., MEHR, A. P., HAMILTON, G. A., MCPARTLIN, L. A., CHUNG, S. Y., SUH, K. Y. & INGBER, D. E. 2013. Human kidney proximal tubule-on-a-chip for drug transport and

nephrotoxicity assessment. *Integrative Biology,* 5, 1119-1129.
JANG, K. J. & SUH, K. Y. 2010. A multi-layer microfluidic device for efficient culture and analysis of renal tubular cells. *Lab on a Chip,* 10, 36-42.
KAMANDE, J. W., HUPERT, M. L., WITEK, M. A., WANG, H., TORPHY, R. J., DHARMASIRI, U., NJOROGE, S. K., JACKSON, J. M., AUFFORTH, R. D., SNAVELY, A., YEH, J. J. & SOPER, S. A. 2013. Modular Microsystem for the Isolation, Enumeration, and Phenotyping of Circulating Tumor Cells in Patients with Pancreatic Cancer. *Analytical Chemistry,* 85, 9092-9100.
KHAN, Z. S. & VANAPALLI, S. A. 2013. Probing the mechanical properties of brain cancer cells using a microfluidic cell squeezer device. *Biomicrofluidics,* 7.
KHNOUF, R., OLIVERO, D., JIN, S. G., COLEMAN, M. A. & FAN, Z. H. 2010. Cell-Free Expression of Soluble and Membrane Proteins in an Array Device for Drug Screening. *Analytical Chemistry,* 82, 7021-7026.
KIM, H. J., HUH, D., HAMILTON, G. & INGBER, D. E. 2012. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. *Lab on a Chip,* 12, 2165-2174.
KIM, P., KWON, K. W., PARK, M. C., LEE, S. H., KIM, S. M. & SUH, K. Y. 2008. Soft lithography for microfluidics: a review. *Biochip Journal,* 2, 1-11.
KIMURA, H., IKEDA, T., NAKAYAMA, H., SAKAI, Y. & FUJII, T. 2015. An On-Chip Small Intestine-Liver Model for Pharmacokinetic Studies. *Jala,* 20, 265-273.
KIMURA, H., YAMAMOTO, T., SAKAI, H., SAKAI, Y. & FUJII, T. 2008. An integrated microfluidic system for long-term perfusion culture and on-line monitoring of intestinal tissue models. *Lab on a Chip,* 8, 741-746.
KLOSTRANEC, J. M., XIANG, Q., FARCAS, G. A., LEE, J. A., RHEE, A., LAFFERTY, E. I., PERRAULT, S. D., KAIN, K. C. & CHAN, W. C. W. 2007. Convergence of quantum dot barcodes with microfluidics and signal processing for multiplexed high-throughput infectious disease diagnostics. *Nano Letters,* 7, 2812-2818.
KOBEL, S. & LUTOLF, M. P. 2010. High-throughput methods to define complex stem cell niches. *Biotechniques,* 48, IX-XXII.
KOBEL, S. & LUTOLF, M. P. 2011. Biomaterials meet microfluidics: building the next generation of artificial niches. *Current Opinion in Biotechnology,* 22, 690-697.
KOLAHCHI, A. R., MOHTARAM, N. K., MODARRES, H. P., MOHAMMADI, M. H., GERAILI, A., JAFARI, P., AKBARI, M. & SANATI-NEZHAD, A. 2016. Microfluidic-Based Multi-Organ Platforms for Drug Discovery. *Micromachines,* 7.
KRAMER, J. A., SAGARTZ, J. E. & MORRIS, D. L. 2007. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. *Nature Reviews Drug Discovery,* 6, 636-649.
KWAK, B., OZCELIKKALE, A., SHIN, C. S., PARK, K. & HAN, B. 2014. Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip. *Journal of Controlled Release,* 194, 157-167.
LAI, S., WANG, S. N., LUO, J., LEE, L. J., YANG, S. T. & MADOU, M. J. 2004. Design of a compact disk-like microfluidic platform for enzyme-linked immunosorbent assay. *Analytical Chemistry,* 76, 1832-1837.
LECLERC, E., HAMON, J. & BOIS, F. Y. 2016. Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models. *Journal of Applied Toxicology,* 36, 330-339.
LEE, J. B. & SUNG, J. H. 2013. Organ-on-a-chip technology and microfluidic whole-body models for pharmacokinetic drug toxicity screening. *Biotechnology Journal,* 8, 1258-1266.
LEE, K. H., SU, Y. D., CHEN, S. J., TSENG, F. G. & LEE, G. B. 2007a. Microfluidic systems integrated with two-dimensional surface plasmon resonance phase imaging systems for microarray immunoassay. *Biosensors & Bioelectronics,* 23, 466-472.
LEE, P. J., HUNG, P. J. & LEE, L. P. 2007b. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. *Biotechnology and Bioengineering,* 97, 1340-1346.

LEE, W. G., KIM, Y.-G., CHUNG, B. G., DEMIRCI, U. & KHADEMHOSSEINI, A. 2010. Nano/Microfluidics for diagnosis of infectious diseases in developing countries. *Advanced Drug Delivery Reviews,* 62**,** 449-457.

LENSHOF, A. & LAURELL, T. 2010. Continuous separation of cells and particles in microfluidic systems. *Chemical Society Reviews,* 39**,** 1203-1217.

LEON, R. A. L., SOMASUNDAR, A., BADRUDDOZA, A. Z. M. & KHAN, S. A. 2015. Microfluidic Fabrication of Multi-Drug-Loaded Polymeric Microparticles for Topical Glaucoma Therapy. *Particle & Particle Systems Characterization,* 32**,** 567-572.

LEVARIO, T. J., ZHAO, C., ROUSE, T., SHVARTSMAN, S. Y. & LU, H. 2016. An integrated platform for large-scale data collection and precise perturbation of live Drosophila embryos. *Scientific Reports,* 6.

LI, H. F. & LIN, J. M. 2009. Applications of microfluidic systems in environmental analysis. *Analytical and Bioanalytical Chemistry,* 393**,** 555-567.

LI, P., STRATTON, Z. S., DAO, M., RITZ, J. & HUANG, T. J. 2013. Probing circulating tumor cells in microfluidics. *Lab on a Chip,* 13**,** 602-609.

LIU, H., CHEN, S., HUANG, K., KIM, J., MO, H., IOVINE, R., GENDRE, J., PASCAL, P., LI, Q., SUN, Y. P., DONE, Z. Q., ARKIN, M., GUO, S. & HUANG, B. 2016. A High-Content Larval Zebrafish Brain Imaging Method for Small Molecule Drug Discovery. *Plos One,* 11.

LIU, M. C., HO, D. & TAI, Y.-C. 2008. Monolithic fabrication of three-dimensional microfluidic networks for constructing cell culture array with an integrated combinatorial mixer. *Sensors and Actuators B: Chemical,* 129**,** 826-833.

LUO, Y., QIN, J. H. & LIN, B. C. 2009. Methods for pumping fluids on biomedical lab-on-a-chip. *Frontiers in Bioscience,* 14**,** 3913-3924.

MA, S. H., THIELE, J., LIU, X., BAI, Y. P., ABELL, C. & HUCK, W. T. S. 2012. Fabrication of Microgel Particles with Complex Shape via Selective Polymerization of Aqueous Two-Phase Systems. *Small,* 8**,** 2356-2360.

MAERKL, S. J. & QUAKE, S. R. 2007. A systems approach to measuring the binding energy landscapes of transcription factors. *Science,* 315**,** 233-237.

MAGUIRE, T. J., NOVIK, E., CHAO, P., BARMINKO, J., NAHMIAS, Y., YARMUSH, M. L. & CHENG, K. C. 2009. Design and Application of Microfluidic Systems for In Vitro Pharmacokinetic Evaluation of Drug Candidates. *Current Drug Metabolism,* 10**,** 1192-1199.

MAHLER, G. J., ESCH, M. B., STOKOL, T., HICKMAN, J. J. & SHULER, M. L. 2016. Body-on-a-chip systems for animal-free toxicity testing. *Alternatives to laboratory animals : ATLA,* 44**,** 469-478.

MANZ, A., GRABER, N. & WIDMER, H. M. 1990. Miniaturized total chemical analysis systems: A novel concept for chemical sensing. *Sensors and Actuators B: Chemical,* 1**,** 244-248.

MARK, D., HAEBERLE, S., ROTH, G., VON STETTEN, F. & ZENGERLE, R. 2010. Microfluidic lab-on-a-chip platforms: requirements, characteristics and applications. *Chemical Society Reviews,* 39**,** 1153-1182.

MASCHMEYER, I., LORENZ, A. K., SCHIMEK, K., HASENBERG, T., RAMME, A. P., HUBNER, J., LINDNER, M., DREWELL, C., BAUER, S., THOMAS, A., SAMBO, N. S., SONNTAG, F., LAUSTER, R. & MARX, U. 2015. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. *Lab on a Chip,* 15**,** 2688-2699.

MASUDA, T., NIIMI, M., NAKANISHI, H., YAMANISHI, Y. & ARAI, F. 2013. Cancer cell separator using size-dependent filtration in microfluidic chip. *Sensors and Actuators, B: Chemical,* 185**,** 245-251.

MATERNE, E.-M., RAMME, A. P., TERRASSO, A. P., SERRA, M., ALVES, P. M., BRITO, C., SAKHAROV, D. A., TONEVITSKY, A. G., LAUSTER, R. & MARX, U. 2015. A multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing. *Journal of Biotechnology,* 205**,** 36-46.

MATOSEVIC, S., SZITA, N. & BAGANZ, F. 2011. Fundamentals and applications of immobilized microfluidic enzymatic reactors. *Journal of Chemical Technology and Biotechnology,* 86**,** 325-334.

MCCAIN, M. L., AGARWAL, A., NESMITH, H. W., NESMITH, A. P. & PARKER, K. K. 2014. Micromolded gelatin hydrogels for extended culture of engineered cardiac tissues. *Biomaterials,* 35, 5462-5471.

MCDONALD, J. C. & WHITESIDES, G. M. 2002. Poly(dimethylsiloxane) as a material for fabricating microfluidic devices. *Accounts of Chemical Research,* 35, 491-499.

MILLER, E. M. & WHEELER, A. R. 2008. A digital microfluidic approach to homogeneous enzyme assays. *Analytical Chemistry,* 80, 1614-1619.

MOON, S., KELES, H. O., OZCAN, A., KHADEMHOSSEINI, A., HÆGGSTROM, E., KURITZKES, D. & DEMIRCI, U. 2009. Integrating microfluidics and lensless imaging for point-of-care testing. *Biosensors and Bioelectronics,* 24, 3208-3214.

NAHER, S., ORPEN, D., BRABAZON, D., POULSEN, C. R. & MORSHED, M. M. 2011. Effect of micro-channel geometry on fluid flow and mixing. *Simulation Modelling Practice and Theory,* 19, 1088-1095.

NAZARENKO, I. 2010. Cell Surface Tetraspanin Tspan8 Contributes to Molecular Pathways of Exosome-Induced Endothelial Cell Activation (vol 70, pg 1668, 2010). *Cancer Research,* 70.

NEUZIL, P., GISELBRECHT, S., LANGE, K., HUANG, T. J. & MANZ, A. 2012. Revisiting lab-on-a-chip technology for drug discovery. *Nature Reviews Drug Discovery,* 11, 620-632.

NGE, P. N., ROGERS, C. I. & WOOLLEY, A. T. 2013. Advances in Microfluidic Materials, Functions, Integration, and Applications. *Chemical Reviews,* 113, 2550-2583.

NGUYEN, N. T., SHAEGH, S. A. M., KASHANINEJAD, N. & PHAN, D. T. 2013. Design, fabrication and characterization of drug delivery systems based on lab-on-a-chip technology. *Advanced Drug Delivery Reviews,* 65, 1403-1419.

OVERINGTON, J. P., AL-LAZIKANI, B. & HOPKINS, A. L. 2006. Opinion - How many drug targets are there? *Nature Reviews Drug Discovery,* 5, 993-996.

PAMME, N. 2007. Continuous flow separations in microfluidic devices. *Lab on a Chip,* 7, 1644-1659.

PARDO-MARTIN, C., CHANG, T. Y., KOO, B. K., GILLELAND, C. L., WASSERMAN, S. C. & YANIK, M. F. 2010. High-throughput in vivo vertebrate screening. *Nature Methods,* 7, 634-U46.

PARK, J. W., VAHIDI, B., TAYLOR, A. M., RHEE, S. W. & JEON, N. L. 2006. Microfluidic culture platform for neuroscience research. *Nature Protocols,* 1, 2128-2136.

PERRIN, D., FREMAUX, C., BESSON, D., SAUER, W. H. B. & SCHEER, A. 2006. A microfluidics-based mobility shift assay to discover new tyrosine phosphatase inhibitors. *Journal of Biomolecular Screening,* 11, 996-1004.

PIHL, J., KARLSSON, M. & CHIU, D. T. 2005. Microfluidic technologies in drug discovery. *Drug Discovery Today,* 10, 1377-1383.

POTERA, C. 2005. Caliper's LabChip systems target discovery. *Genetic Engineering News,* 25, 44-45.

PREGIBON, D. C., TONER, M. & DOYLE, P. S. 2007. Multifunctional encoded particles for high-throughput biomolecule analysis. *Science,* 315, 1393-1396.

REN, K., ZHOU, J. & WU, H. 2013. Materials for Microfluidic Chip Fabrication. *Accounts of Chemical Research,* 46, 2396-2406.

REYES, D. R., IOSSIFIDIS, D., AUROUX, P. A. & MANZ, A. 2002. Micro total analysis systems. 1. Introduction, theory, and technology. *Analytical Chemistry,* 74, 2623-2636.

RIAHI, R., TAMAYOL, A., SHAEGH, S. A. M., GHAEMMAGHAMI, A. M., DOKMECI, M. R. & KHADEMHOSSEINI, A. 2015. Microfluidics for advanced drug delivery systems. *Current Opinion in Chemical Engineering,* 7, 101-112.

RIOS, A., ZOUGAGH, M. & AVILA, M. 2012. Miniaturization through lab-on-a-chip: Utopia or reality for routine laboratories? A review. *Analytica Chimica Acta,* 740, 1-11.

RUBIN, L. L. & HASTON, K. M. 2011. Stem cell biology and drug discovery. *Bmc Biology,* 9.

SACKMANN, E. K., FULTON, A. L. & BEEBE, D. J. 2014. The present and future role of microfluidics in biomedical research. *Nature,* 507, 181-189.

SAMAD, M. F. & KOUZANI, A. Z. 2013. Integrated microfluidic drug delivery devices: a component view. *Microsystem Technologies-Micro-and Nanosystems-Information Storage and*

Processing Systems, 19, 957-970.
SIA, S. K. & WHITESIDES, G. M. 2003. Microfluidic devices fabricated in poly(dimethylsiloxane) for biological studies. *Electrophoresis,* 24, 3563-3576.
SKARDAL, A., SHUPE, T. & ATALA, A. 2016. Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. *Drug Discovery Today,* 21, 1399-1411.
SMITH, S., TANG, T. B., TERRY, J. G., STEVENSON, J. T. M., FLYNN, B. W., REEKIE, H. M., MURRAY, A. F., GUNDLACH, A. M., RENSHAW, D., DHILLON, B., OHTORI, A., INOUE, Y. & WALTON, A. J. 2007. Development of a miniaturised drug delivery system with wireless power transfer and communication. *Iet Nanobiotechnology,* 1, 80-86.
STOTT, S. L., HSU, C. H., TSUKROV, D. I., YU, M., MIYAMOTO, D. T., WALTMAN, B. A., ROTHENBERG, S. M., SHAH, A. M., SMAS, M. E., KORIR, G. K., FLOYD, F. P., GILMAN, A. J., LORD, J. B., WINOKUR, D., SPRINGER, S., IRIMIA, D., NAGRATH, S., SEQUIST, L. V., LEE, R. J., ISSELBACHER, K. J., MAHESWARAN, S., HABER, D. A. & TONER, M. 2010. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. *Proceedings of the National Academy of Sciences of the United States of America,* 107, 18392-18397.
SUCHORSKA, W. M. & LACH, M. S. 2016. The role of exosomes in tumor progression and metastasis. *Oncology Reports,* 35, 1237-1244.
SUNG, J. H., KAM, C. & SHULER, M. L. 2010. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. *Lab on a Chip,* 10, 446-455.
SUNG, J. H. & SHULER, M. L. 2009. A micro cell culture analog (mu CCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. *Lab on a Chip,* 9, 1385-1394.
SUNG, K. E., YANG, N., PEHLKE, C., KEELY, P. J., ELICEIRI, K. W., FRIEDL, A. & BEEBE, D. J. 2011. Transition to invasion in breast cancer: a microfluidic in vitro model enables examination of spatial and temporal effects. *Integrative Biology,* 3, 439-450.
SWEENEY, L. M., SHULER, M. L., BABISH, J. G. & GHANEM, A. 1995. A CELL-CULTURE ANALOG OF RODENT PHYSIOLOGY - APPLICATION TO NAPHTHALENE TOXICOLOGY. *Toxicology in Vitro,* 9, 307-316.
TEKIN, H., OZAYDIN-INCE, G., TSINMAN, T., GLEASON, K. K., LANGER, R., KHADEMHOSSEINI, A. & DEMIREL, M. C. 2011. Responsive Microgrooves for the Formation of Harvestable Tissue Constructs. *Langmuir,* 27, 5671-5679.
TERRY, S. C., JERMAN, J. H. & ANGELL, J. B. 1979. Gas-chromatographic air analyzer fabricated on a silicon-wafer. *Ieee Transactions on Electron Devices,* 26, 1880-1886.
TETTA, C., GHIGO, E., SILENGO, L., DEREGIBUS, M. C. & CAMUSSI, G. 2013. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. *Endocrine,* 44, 11-19.
TOH, Y. C., LIM, T. C., TAI, D., XIAO, G. F., VAN NOORT, D. & YU, H. R. 2009. A microfluidic 3D hepatocyte chip for drug toxicity testing. *Lab on a Chip,* 9, 2026-2035.
TSAO, C. W. & DEVOE, D. L. 2009. Bonding of thermoplastic polymer microfluidics. *Microfluidics and Nanofluidics,* 6, 1-16.
VAN MIDWOUD, P. M., MEREMA, M. T., VERPOORTE, E. & GROOTHUIS, G. M. M. 2010. A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. *Lab on a Chip,* 10, 2778-2786.
VAN MIDWOUD, P. M., VERPOORTE, E. & GROOTHUIS, G. M. M. 2011. Microfluidic devices for in vitro studies on liver drug metabolism and toxicity. *Integrative Biology,* 3, 509-521.
VIRAVAIDYA, K. & SHULER, M. L. 2004. Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. *Biotechnology Progress,* 20, 590-597.
VIRAVAIDYA, K., SIN, A. & SHULER, M. L. 2004. Development of a microscale cell culture analog to probe naphthalene toxicity. *Biotechnology Progress,* 20, 316-323.
VLADISAVLJEVIC, G. T., KHALID, N., NEVES, M. A., KUROIWA, T., NAKAJIMA, M., UEMURA, K., ICHIKAWA, S. & KOBAYASHI, I. 2013. Industrial lab-on-a-chip: Design, applications and scale-up for drug discovery and delivery. *Advanced Drug Delivery Reviews,* 65, 1626-1663.

WANG, B., NI, J., LITVIN, Y., PFAFF, D. W. & LIN, Q. 2012. A Microfluidic Approach to Pulsatile Delivery of Drugs for Neurobiological Studies. *Journal of Microelectromechanical Systems,* 21**,** 53-61.

WANG, J. M., LI, Y., WANG, X. Y., WANG, J. C., TIAN, H. M., ZHAO, P., TIAN, Y., GU, Y. M., WANG, L. Q. & WANG, C. Y. 2017. Droplet Microfluidics for the Production of Microparticles and Nanoparticles. *Micromachines,* 8.

WANG, Z. H., MENG, Y. H., YING, P. Q., QI, C. & JIN, G. 2006. A label-free protein microfluidic array for parallel immunoassays. *Electrophoresis,* 27**,** 4078-4085.

WEIGL, B. H., BARDELL, R. L. & CABRERA, C. R. 2003. Lab-on-a-chip for drug development. *Advanced Drug Delivery Reviews,* 55**,** 349-377.

WIKSWO, J. P., CURTIS, E. L., EAGLETON, Z. E., EVANS, B. C., KOLE, A., HOFMEISTER, L. H. & MATLOFF, W. J. 2013. Scaling and systems biology for integrating multiple organs-on-a-chip. *Lab on a Chip,* 13**,** 3496-3511.

WOOD, D. K., WEINGEIST, D. M., BHATIA, S. N. & ENGELWARD, B. P. 2010. Single cell trapping and DNA damage analysis using microwell arrays. *Proceedings of the National Academy of Sciences of the United States of America,* 107**,** 10008-10013.

WU, M. H., HUANG, S. B. & LEE, G. B. 2010. Microfluidic cell culture systems for drug research. *Lab on a Chip,* 10**,** 939-956.

WU, M. H., URBAN, J. P. G., CUI, Z. & CUI, Z. F. 2006. Development of PDMS microbioreactor with well-defined and homogenous culture environment for chondrocyte 3-D culture. *Biomedical Microdevices,* 8**,** 331-340.

WU, Z. Y., XANTHOPOULOS, N., REYMOND, F., ROSSIER, J. S. & GIRAULT, H. H. 2002. Polymer microchips bonded by O-2-plasma activation. *Electrophoresis,* 23**,** 782-790.

XU, Z. Y., GAO, Y. H., HAO, Y. Y., LI, E. C., WANG, Y., ZHANG, J. N., WANG, W. X., GAO, Z. C. & WANG, Q. 2013. Application of a microfluidic chip-based 3D co-culture to test drug sensitivity for individualized treatment of lung cancer. *Biomaterials,* 34**,** 4109-4117.

YANG, S. T., ZHANG, X. D. & WEN, Y. 2008. Microbioreactors for high-throughput cytotoxicity assays. *Current Opinion in Drug Discovery & Development,* 11**,** 111-127.

YILDIZ, I. 2016. Applications of magnetic nanoparticles in biomedical separation and purification. *Nanotechnology Reviews,* 5**,** 331-340.

ZHANG, C., ZHAO, Z. Q., RAHIM, N. A. A., VAN NOORT, D. & YU, H. 2009. Towards a human-on-chip: Culturing multiple cell types on a chip with compartmentalized microenvironments. *Lab on a Chip,* 9**,** 3185-3192.

ZHENG, B., ROACH, L. S. & ISMAGILOV, R. F. 2003. Screening of protein crystallization conditions on a microfluidic chip using nanoliter-size droplets. *Journal of the American Chemical Society,* 125**,** 11170-11171.

ZHENG, F., FU, F., CHENG, Y., WANG, C., ZHAO, Y. & GU, Z. 2016a. Organ-on-a-Chip Systems: Microengineering to Biomimic Living Systems. *Small,* 12**,** 2253-2282.

ZHENG, F. Y., FU, F. F., CHENG, Y., WANG, C. Y., ZHAO, Y. J. & GU, Z. Z. 2016b. Organ-on-a-Chip Systems: Microengineering to Biomimic Living Systems. *Small,* 12**,** 2253-2282.

ZHENG, Y., CHEN, J. M., CRAVEN, M., CHOI, N. W., TOTORICA, S., DIAZ-SANTANA, A., KERMANI, P., HEMPSTEAD, B., FISCHBACH-TESCHL, C., LOPEZ, J. A. & STROOCK, A. D. 2012. In vitro microvessels for the study of angiogenesis and thrombosis. *Proceedings of the National Academy of Sciences of the United States of America,* 109**,** 9342-9347.

ZHOU, J. W., ELLIS, A. V. & VOELCKER, N. H. 2010. Recent developments in PDMS surface modification for microfluidic devices. *Electrophoresis,* 31**,** 2-16.

ZHU, P. A. & WANG, L. Q. 2017. Passive and active droplet generation with microfluidics: a review. *Lab on a Chip,* 17**,** 34-75.